about
The role of incretin therapy at different stages of diabetes.Glucagon-like peptide-1 inhibits vascular smooth muscle cell dedifferentiation through mitochondrial dynamics regulation.Therapy in the early stage: incretins.Putting medications where they belong: practical advice for managing type 2 diabetes in clinical practice.Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes.
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Incretin therapies: effects beyond glycemic control.
@en
type
label
Incretin therapies: effects beyond glycemic control.
@en
prefLabel
Incretin therapies: effects beyond glycemic control.
@en
P1476
Incretin therapies: effects beyond glycemic control.
@en
P2093
Robert R Henry
Sunder Mudaliar
P304
P356
10.1016/J.EJIM.2009.05.010
P478
20 Suppl 2
P577
2009-06-21T00:00:00Z